HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

Launched by YALE UNIVERSITY · Jul 15, 2024

Keywords

ClinConnect Summary

The HARP Pilot 2 trial is studying how alcohol, cannabis use, and certain medications affect falls and thinking skills in people living with HIV. Researchers want to understand how these factors might lead to falls or problems with memory and concentration. This study is important because even small amounts of alcohol can interact with medications that affect the brain, potentially putting individuals at risk.

To participate in this trial, you need to be HIV positive, have visited a VA site in the past year, and currently use alcohol. Additionally, you should be taking five or more non-HIV medications that can influence brain function, like those used for anxiety or sleep. However, you cannot be currently hospitalized, diagnosed with a serious drinking problem in the last year, or show signs of moderate to severe alcohol issues during screening. If eligible, participants can expect to contribute to important research that may help improve care for others in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • HIV+
• • have visited a local VA site in within the past year
• • had an AUDIT-C indicating current alcohol use
• • taking 5 or more non-ART medications, including an NCAM (i.e., benzodiazepines, opioids, muscle relaxants, sleeping medication, and selective serotonin reuptake inhibitors)
• Exclusion Criteria:
• • Inpatient individuals
• • Patients with an Alcohol Use Disorder (AUD) diagnosis in the past 12 months
• • Patients who test positive on the Alcohol Symptom Checklist for moderate or severe AUD during the screening process